Navigation Links
Favrille Announces Resolution of Debt Obligations and Plans for Maximizing Assets
Date:7/7/2008

SAN DIEGO, July 7 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL) today announced that it has come to an agreement with its secured creditors, General Electric Capital Corporation and Oxford Financial Corporation (Lenders). The agreement follows Favrille's recent announcement that the Lenders had received approximately $8.8 million as repayment of the outstanding principal, accrued interest and certain costs. Acceleration of the loan was triggered when the Company's cash fell below the $14.5 million minimum cash covenant on May 30, 2008. Under terms of the agreement, the Company reimbursed the Lenders an additional $47,000 of transaction costs. The Lenders have been paid in full and, therefore, have agreed to release the general lien on the Company's assets.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080404/LAF521LOGO)

Following the recent announcement that the Phase 3 registration trial for its lead product, Specifid(TM), failed to demonstrate activity, Favrille announced it would cease all activities related to Specifid and other programs requiring production of patient-specific therapies including the T-cell and autoimmune disease programs. The Company laid off 132 of its 144 employees, including six of its eight executive officers, effective June 6, 2008. In addition, the Company plans to sell all unneeded fixed assets in the near future.

Favrille is currently in discussions with its landlord regarding the terms of the existing lease agreement in light of the fact that the Company does not require, nor can it meet the obligations for, the GMP manufacturing facility designed for the manufacture of Specifid. The Company intends to maximize the value of its other assets, including the panel of humanized anti-CD20 antibodies acquired from Diversa (now Verenium) in 2007.

"We have received a number of inquiries regarding the manufacturing fa
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
2. Favrille CEO to Present at Bear Stearns Healthcare Conference
3. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
4. Favrille to Present at BIO InvestorForum
5. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
6. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
7. Favrille Announces $21.1 Million Registered Direct Offering
8. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
9. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
10. Favrille Reports First Quarter 2008 Financial Results
11. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Carahsoft and CDS Federal Services have ... at 2pm EST (11am PST), “Natural Language Processing: Converting ... how technology can turn raw, heterogeneous data into actionable ... The online webinar will last approximately one hour. , ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... 2014 In recent years, growing suspicion ... in product development and promotion has led to unprecedented ... fueled by concerns about the insidious impact of commercialization ... spectacular fines to the world’s biggest pharmas for illegal ...
(Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... Calif., April 4, 2011 MedeAnalytics announced today the ... proposed rule for the Medicare Shared Savings Program issued ... March 31, 2011. (Logo:   http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) ... Summary and Analysis of the Proposed Rule," covers a ...
... reveals a potentially highly effective treatment for heterotopic ossification ... bone tissue. HO comes in two main forms—one that ... wounded military personnel and surgery patients and is triggered ... animal study by developmental biologists shows that a drug ...
... SAN DIEGO, April 1, 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: ... 2011 the Compensation Committee of its Board of Directors approved ... of 258,000 shares of common stock to 7 new employees. ... option has an exercise price per share equal to $11.83, ...
Cached Biology Technology:ACO Proposed Rule Simplified: MedeAnalytics Releases Comprehensive White Paper 2Potential Treatment Found for Debilitating Bone Disease in Wounded Soldiers and Children 2Potential Treatment Found for Debilitating Bone Disease in Wounded Soldiers and Children 3Potential Treatment Found for Debilitating Bone Disease in Wounded Soldiers and Children 4Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 2
(Date:4/17/2014)... is the process whereby the genetic information of ... as proteins, which have numerous different functions in ... important intermediary during gene expression, by relating the ... involved in manufacturing proteins. , By examining ... present in an organism at a given time, ...
(Date:4/17/2014)... Scientists have uncovered a new way the immune system ... aid efforts to use immune cells to treat illness. ... have the immunological equivalent of "neighborhood police" specialized ... single organ, instead of an entire city, the body. ... St. Louis have shown that the liver, skin and ...
(Date:4/17/2014)... derive from Charles Darwin, whose ideas in turn ... the 19th century, a period when landowners vigorously ... from Darwin that we inherit the ideas that ... species and total human control over breeding and ... industrial setting has been applied too broadly in ...
Breaking Biology News(10 mins):Rapid and accurate mRNA detection in plant tissues 2Some immune cells defend only 1 organ 2The story of animal domestication retold 2The story of animal domestication retold 3The story of animal domestication retold 4
... time that embryonic stem (ES) cells cultured in the ... viable offspring. The research, published in the July issue ... studies, including investigation of mechanisms involved in sperm production ... Previous studies have shown that ES cells grown in ...
... San Diego have developed what they call a "Smart ... new drugs for toxic interactions or identify cells in ... blood. , Their invention, described in the June 20 ... the American Chemical Society, uses porous silicon crystals filled ...
... lend new insight into the mechanism of genomic imprinting, ... in the silencing of an imprinted gene cluster in ... gene based upon which parent it has been inherited ... human disorders, Prader-Willi and Angelman syndromes, result from the ...
Cached Biology News:Sperm created in the laboratory from embryonic stem cells produce viable progeny 2UCSD researchers develop 'smart petri dish' 2UCSD researchers develop 'smart petri dish' 3
...
Carbonate-Bicarbonate Buffer Capsules. For use in coating ELISA plates. Dissolve contents of 1 capsule in 100 ml deionized water to yield 0.05 M carbonate-bicarbonate buffer, pH 9.6....
Immunogen: Synthetic peptide: S(399) P W S E L E F Q F P D D K D P V W E F(418) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: